- PAX-101 demonstrated sustained improvements over placebo in the trial's primary and several secondary endpoints and a favorable safety and tolerability profile - Results build upon data from a prior published pilot study, with new insights on the relationship between dose, efficacy and response over 14 weeks of treatment with… Read More..
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced participation in a series of 1x1 meetings with institutional investors at the 10th Annual SV Leerink Global Healthcare Conference, occurring February 24 – 26, 2021. To… Read More..
New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company's plans for commercializing its ground-breaking SGX301 candidate… Read More..